Safety and efficacy comparison of remimazolam and propofol for intravenous anesthesia during gastroenteroscopic surgery of older patients: A meta-analysis.

Background: Remimazolam is characterized by rapid action and inactive metabolites. It is used as the general anesthetic for many clinical surgeries. In this study, we performed a meta-analysis to evaluate whether remimazolam is superior to propofol for gastroenteroscopy in older patients.

Aim: To compare the adverse events and efficacy of remimazolam and propofol during gastroenteroscopy in older adults.

Methods: The PubMed, Web of Science, the Cochrane Library databases were queried for the relevant key words "remimazolam," "and propofol," "and gastrointestinal endoscopy or gastroscopy." The search scope was "Title and Abstract," and the search was limited to human studies and publications in English. Seven studies wherein remimazolam and propofol were compared were included for the meta-analysis.

Results: We selected seven randomized controlled trials involving 1445 cases for the analysis. Remimazolam reduced the hypotension (relative risk, RR = 0.44, 95%CI: 0.29-0.66, = 0.000), respiratory depression (RR = 0.46, 95%CI: 0.30-0.70, = 0.000), injection pain (RR = 0.12, 95%CI: 0.05-0.25, = 0.000), bradycardia (RR = 0.37, 95%CI: 0.24-0.58, = 0.000), and time to discharge [weighted mean difference (WMD) = -0.58, 95%CI: -0.97 to -0.18, = 0.005], compared to those after propofol administration. No obvious differences were observed for postoperative nausea and vomiting (RR = 1.09, 95%CI: 0.97-1.24, = 0.151), dizziness (RR = 0.77, 95%CI: 0.43-1.36, = 0.361), successful sedation rate (RR = 0.96, 95%CI: 0.93-1.00, = 0.083), or the time to become fully alert (WMD = 0.00, 95%CI: -1.08-1.08, = 0.998).

Conclusion: Remimazolam appears to be safer than propofol for gastroenteroscopy in older adults. However, further studies are required to confirm these findings.